Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Mind Medicine Mindmed Inc (NQ: MNMD ) 6.610 +0.190 (+2.96%) Streaming Delayed Price Updated: 4:00 PM EDT, Oct 18, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Mind Medicine Mindmed Inc < Previous 1 2 ... 25 26 27 28 29 30 31 32 Next > Psychedelics Gain More Traction as New Research Aims to Address Chronic Pain and Mental Illness July 21, 2021 Via FinancialNewsMedia Topics Law Enforcement Exposures Legal Mind Medicine Has More Obstacles Than Opportunities July 20, 2021 MNMD stock could revolutionize mental healthcare with its novel therapeutics, but there are currently too many risks with its business. Via InvestorPlace Psychedelic Decriminalization Creating Market Opportunities July 12, 2021 Via FinancialNewsMedia Topics Cannabis Law Enforcement Exposures Cannabis Legal Psyched: Numinus, MindMed, Cybin Reach Milestones, Harvard To Study Psychedelics Law, Michael Pollan Dives Into Mescaline July 12, 2021 Michael Pollan’s New Book Takes A Deep Dive Into Mescaline – Will This Be A Turning Point For The Recognition And Study of&n... Via Benzinga How To Invest In "Magic Mushrooms" (Psychedelics) July 09, 2021 A look at psychedelics as stock market investment opportunities and identifying alternative strategies on how to invest. Via Talk Markets MindMed Stock Is Overvalued and Too Risky to Own July 08, 2021 MindMed can be the future of psychedelic medicines, but without cash flow from revenue, MNMD stock is nothing to get excited about. Via InvestorPlace Psychedelics Research FYI: Every Clinical Trial Underway Right Now Involving Public And Private Companies July 07, 2021 This article was made possible thanks to invaluable research by Michael Haichin and Josh Hardman from Ps... Via Benzinga The 6 Leading Psychedelic Stocks In Drug R&D July 07, 2021 Drug R&D in the emerging psychedelic drug industry continues to advance. Share prices continue to lag. Here's a comparison of the strengths and weaknesses of six of the leaders in psychedelic drug R&D... Via Talk Markets Rising Prevalence of Mental Depression & Anxiety Major Drivers Propelling Demand In Psychedelic Drugs Market July 07, 2021 Via FinancialNewsMedia Psyched: GH Research Debuts on Nasdaq, Compass Reaches Psilocybin Research Milestone, Maxim Gives BUY Rating to 10 Psychedelics Companies July 02, 2021 Irish 5-MeO-DMT Company GH Research Debuts On Nasdaq GH Research, a Dublin-based company studying the potential o... Via Benzinga The MindMed Psychedelic Revolution Will Take Years to Come to Fruition July 02, 2021 MNMD stock aspires to be a lot to many but could flop. Prices are low, risk is high and speculators could become savants. Via InvestorPlace Maxim Group Gives Buy Rating To 10 Psychedelic Stocks: Compass, MindMed, Cybin, Field Trip And More June 30, 2021 Institutional analysts are taking a liking to the industry ... Via Benzinga Video: Talking Cannabis With Aurora Co-Founder Terry Booth | Benzinga Cannabis Insider 6/29 June 30, 2021 Benzinga’s Via Benzinga Topics Cannabis Exposures Cannabis Get a Dose of Innovative Science With Mind Medicine June 29, 2021 MNMD stock ran high last year, but the story is still being written as Mind Medicine marks progress with its psychedelics-based treatments. Via InvestorPlace Psychedelics-Focused MindMed Joins FTSE Russell 3000 Index, 'A True Honor' June 29, 2021 A psychedelics-focused medicine company MindMed (NASDAQ: Via Benzinga Pandemic Fallout: 6 Mental Health Stocks To Watch June 28, 2021 One of the most devastating long-term impacts of the COVID-19 pandemic may be the toll it has taken on people’s mental health. The next globa... Via Benzinga Exposures COVID-19 MindMed Can Play a Big Role in the Growing Mental Wellness Industry June 28, 2021 With Covid-19 increasing the frequency of mental health problems, MNMD stock is a way to invest in psychedelics, which are seeing legitimacy. Via InvestorPlace Exposures COVID-19 Why This MindMed Analyst Is Bullish: 'One Of The Most Diverse Pipelines In Psychedelics' June 28, 2021 Mind Medicine (MindMed) Inc (NASDAQ:MNMD) shares traded hi... Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For June 28, 2021 June 28, 2021 Upgrades For Toll Brothers Inc (NYSE: Via Benzinga Cannabis Movers & Shakers: HempFusion, Decibel, ARCA, Love Hemp, MindMed, Halo June 25, 2021 HempFusion Wellness Promotes VP And Controller Maria Leal To Interim CFO HempFusion Wellness Inc. (TSX: Via Benzinga Topics Cannabis Exposures Cannabis Atai IPO Day An Underwhelming Event June 21, 2021 The IPO of atai Life Sciences was arguably the most-anticipated event in the emerging psychedelic drug industry. It failed to live up to expectations. Via Talk Markets Topics Initial Public Offering Exposures Securities Market Psyched: Atai Life Sciences Hits Nasdaq, Canada To Fund Ketamine Trials, Mydecine Launches AI Drug-Discovery Platform June 21, 2021 Atai Life Sciences (NASDAQ: ATAI) made its highly-anticipated Nasdaq... Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Peter Thiel-backed Psychedelics Company Rings Nasdaq Bell: Atai Life Sciences Goes Public June 18, 2021 Atai Life Sciences (NASDAQ:ATAI), a biotech company in the... Via Benzinga New Psychedelic Drug Stock To Debut After Upsized IPO Prices At High End June 18, 2021 Atai Life Sciences, a backer of psychedelic-drug developers, will start trading Friday, after an upsized offering for the Atai IPO. Via Investor's Business Daily Topics Initial Public Offering Exposures Securities Market Is Mind Medicine a Buy? June 17, 2021 It offers a great way to tap into the psychedelics market -- but is it too risky of an investment right now? Via The Motley Fool Topics Cannabis Exposures Cannabis Could Mind Medicine Be a Millionaire-Maker Stock? June 16, 2021 Yes, but with the chance of great reward comes substantial risk. Via The Motley Fool Recent Surge for Intellectual Property & Patents in Psychedelic Therapies & Drug Development June 15, 2021 Via FinancialNewsMedia Topics Intellectual Property Exposures Intellectual Property Psyched: Atai's $214M IPO, MindMed CEO Resigns, Field Trip Applies To Nasdaq, Cybin And Novamind Target Frontline Health Workers June 14, 2021 Atai Launches $214 Million Nasdaq IPO Offering Psychedelics biotech platform Atai life Sciences has announced an initi... Via Benzinga Topics Initial Public Offering Exposures Securities Market Mind Medicine Stock Might Still Be Worth the Risk Here June 11, 2021 The rampant addiction crisis in America requires a new effective solution, which may suit MNMD stock well. Via InvestorPlace EXCLUSIVE: Psychedelics Pioneer J.R. Rahn Unpacks Decision To Leave MindMed As CEO June 10, 2021 Mind Medicine (MindMed) Inc (NASDAQ: MNMD) (NEO: MMED), a biotech company focused on the field of psychedelics, formally announced this week that J.R. Rahn, the company’s co... Via Benzinga < Previous 1 2 ... 25 26 27 28 29 30 31 32 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.